Top-News

Citius Pharmaceuticals Aktie News

Aktie
WKN:  A40MD0 ISIN:  US17322U3068 US-Symbol:  CTXR Branche:  Pharmazeutika Land:  USA
1,18 $
-0,07 $
-5,60%
1,0134 € 05.12.25
Depot/Watchlist
Marktkapitalisierung *
6,52 Mio. €
Streubesitz
76,16%
KGV
-
Index-Zuordnung
-

Citius Pharmaceuticals News

10.06.25 - PR Newswire
Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules
Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-​The-Market Under Nasdaq Rules PR Newswire
09.06.25 - PR Newswire
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health PR Newswire
14.05.25 - PR Newswire
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update PR Newswire
05.05.25 - PR Newswire
Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference PR Newswire
01.04.25 - PR Newswire
Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock
Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock PR Newswire
14.02.25 - PR Newswire
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update PR Newswire
06.02.25 - PR Newswire
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services PR Newswire
08.01.25 - PR Newswire
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-​The-Market under Nasdaq Rules PR Newswire
07.01.25 - PR Newswire
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 PR Newswire
06.01.25 - PR Newswire
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives PR Newswire
27.12.24 - PR Newswire
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update PR Newswire

Newssuche

Videos

newspaper
05.12.25 +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »